Treatment strategies of bilateral upper urinary tract urothelial carcinoma：clinical analysis of 30 cases

doi:10.3969/j.issn.1006-7795.2014.03.005

Abstract

Abstract:

Objective To explore the clinical treatment strategies of bilateral upper tract urothelial carcinoma. Methods Retrospective analysis of 30 cases who underwent operation for primary bilateral upper urinary tract urothelial carcinoma from January 2002 to May 2011 was performed. Patients were divided into 3 groups according to renal function: group A(eGFR≥60 mL/min), group B(15 mL/min≤eGFR<60 mL/min), group C(eGFR<15 mL/min). The main treatment for group A&B was unilateral nephron-sparing surgery and contralateral radical resection, and for Group C was bilateral radical excision. We analyzed treatment results of patients with different renal function. Results Surgeries on all cases were successful. Postoperative follow-up, showed that bladder tumor recurrence rate was 33.33% in group A; one patient needed dialysis and 1 patient died of tumor. In group B, urothelial tumor recurrence rate was 31.25%.Three patient needed dialysis and another 3 patients died of tumor. The rate of urothelial tumor recurrence in group C is 37.5%, and 3 patients died during the follow-up period. All patients needed dialysis in group C after operation. Conclusion Renal function and tumor characteristics are important in surgery selections of bilateral upper urinary tract urothelial tumors. Nephron-sparing surgery can be used as a alternative treatment.

Key words: bilateral, upper urinary tract urothelial carcinoma, surgical treatment, renal function

CLC Number:

R693

Kang Yongming, Fang Dong, Li Xuesong, Zhou Liqun. Treatment strategies of bilateral upper urinary tract urothelial carcinoma：clinical analysis of 30 cases[J]. Journal of Capital Medical University, 2014, 35(3): 290-294.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2014.03.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2014/V35/I3/290

References

[1] Holmang S, Johansson S L. Synchronous bilateral ureteral and renal pelvic carcinomas: incidence, etiology, treatment and outcome[J]. Cancer, 2004, 101(4):741-747.
[2] Ma Y C, Zuo L, Chen J H, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease[J]. J Am Soc Nephrol, 2006, 17(10):2937-2944.
[3] Nortier J L, Martinez M C, Schmeiser H H, et al.Urothelial carcinoma associated with the use of a Chinese herb(Aristolochia fangchi)[J]. N Engl J Med, 2000, 342(23):1686-1692.
[4] 李卫华, 杨莉, 苏涛, 等.服用含马兜铃酸成分药物对尿毒症透析患者伴发尿路移行细胞癌的影响[J].中华医学杂志, 2005, 85(35):2487-2491.
[5] Vanherweghem J L, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women:association with slimming regimen including Chinese herbs[J]. Lancet, 1993, 341(8842):387-391.
[6] Stefanovic V, Radovanovic Z. Balkan endemic nephropathy and associated urothelial cancer[J]. Nat Clin Pract Urol, 2008, 5(2):105-112.
[7] Cosyns J P, Jadoul M, Squifflet J P, et al.Urothelial lesions in Chinese-herb nephropathy[J]. Am J Kidney Dis, 1999, 33(6):1011-1017.
[8] Clark P E, Streem S B. Endourologic management of upper tract transitional cell carcinoma[J]. Scientific World Journal, 2004, 4(Suppl 1):62-75.
[9] Soderdahl D W, Fabrizio M D, Rahman N U, et al.Endoscopic treatment of upper tract transitional cell carcinoma[J]. Urol Oncol, 2005, 23(2):114-122.
[10] Tawfiek E R, Bagley D H. Upper tract transitional cell carcinoma[J]. Urology, 1997, 50(3):321-329.
[11] Elliott D S, Segura J W, Lightner D, et al.Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney[J]. Urology, 2001, 58(2):174-178.
[12] Azemar M D, Comperat E, Richard F, et al. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance[J]. Urol Oncol, 2011, 29(2):130-136.
[13] Colin P, Ouzzane A, Pignot G, et al.Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study[J]. BJU Int, 2012, 110(8):1134-1141.
[14] Gadzinski A J, Roberts W W, Faerber G J, et al. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma[J]. J Urol, 2010, 183(6):2148-2153.
[15] Zigeuner R, Pummer K. Urothelial carcinoma of the upper urinary tract:surgical approach and prognostic factors[J]. Eur Urol, 2008, 53(4):720-731.
[16] Roupret M, Babjuk M, Comperat E, et al.European guidelines on upper tract urothelial carcinomas: 2013 update[J]. Eur Urol, 2013, 63 (6):1059-1071.
[17] Huang W W, Huang H Y, Liao A C, et al.Primary urothelial carcinoma of the upper tract:important clinicopathological fators predicting bladder recurrence after surgical resection[J]. Pathol Int, 2009, 59(9):642-649.
[18] Pieras E, Frontera G, Ruiz X, et al. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma[J]. BJU int, 2010, 106(9):1319-1323.